A federal jury in Marshall, Texas, found that a Japanese pharmaceutical company infringed on a cancer treatment patent that a U.S. global biotech company developed.

The four-day trial concluded, and jurors awarded Seagen, a Bothell, Washington-based company, $41.8 million. U.S. Chief Judge Rodney Gilstrap presided over the case in the U.S. District Court of the Eastern District of Texas.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]